Skip to content

Three things we are watching

Tariff rollback: 2026 could be the year where US President Trump rolls back his punitive tariffs to a baseline of 10%. Under pressure from elevated food prices, the United States has already announced cuts to tariffs on agricultural imports from Argentina and Brazil. Emerging markets (EMs) could be the primary beneficiaries of a broadening in this pivot in 2026, given they were among the countries hardest hit by tariffs in the Liberation Day announcement.

India/US trade deal by year-end: The United States is expected to announce the completion of its Framework Trade Deal with India by the end of December. This is expected to reduce the current 50% tariffs on India’s exports to the United States to 10%-15%. However, agreement on the more ambitious Bilateral Trade Agreement (BTA), which is expected to include a lowering of India’s tariff and non-tariff barriers for US agricultural exports, remains a challenge. Aside from reducing barriers to agricultural imports, the goal of the BTA is to increase US/India trade in goods and services from US$210 billion in 2024 to US$300 billion by 2030.1

Russia-Ukraine peace deal. Expectations of a peace deal between Russia and Ukraine have increased following the leak of the 28-point peace plan created by US negotiators. If a peace deal is successful, it could exert downward pressure on energy and agricultural commodity prices, given the importance of Russia and Ukraine exports of crude oil, gas, wheat and oil seeds. Lower commodity prices would be positive for inflation in developed markets, creating scope for additional interest-rate cuts in 2026. This could result in further US-dollar weakness, which would be positive for emerging markets.

Outlook

Chinese equities received a recent boost from the country’s anti-involution push, which aims to reduce price competition and industrial overcapacity. Manufacturing and high-technology sectors were focal points of this movement, which became formal and expanded during 2025. The investment team met with some strategic advisors to glean more insight into this reform.

A central objective of the anti-involution push is to generate additive innovation. In a hyper‑competitive environment, price wars and constant defensive spending erode profit margins across an industry, including for market leaders. By contrast, policymakers prefer a smaller number of financially stronger champions in each sector, rather than many weaker players, so that leading companies can reinvest their profits in innovation and research and development, reinforcing China’s broader industrial ecosystem.

Translating this objective into measurable outcomes is challenging because there is no formal metric system, but several indicators offer useful clues. Rising profitability among industry leaders is one sign, while broader margin improvement across entire supply chains is another. Greater international competitiveness would also signal progress: As Chinese firms move up the value chain, more “national champions” may emerge in advanced manufacturing, shifting from volume-driven growth toward higher-value, innovation-led offerings. For example, contract manufacturers could develop proprietary technologies and e-commerce platforms could expand into areas such as cloud computing.

There are also more ambiguous measures of success. Over time, improvements in overall well‑being, consumer confidence and even birth rates could suggest that the pressure of involution is easing and that the nation is sharing economic gains more sustainably.

The risk of a less successful anti-involution policy may have implications for investors worldwide. Continuous profit pressures and misallocation of capital may have negative implications, given China’s central role in many supply chains. However, China’s policies are greatly tied to national priorities. As investors in Chinese equities, our investment process has a top-down overlay to cater to the importance of policy direction in the country. Our China equity funds also favour leaders in their respective industries, as these companies also offer their own competitive advantages. We therefore believe that the anti-involution movement may provide a boost to well-managed companies with sustainable competitive advantages.

EMs are not homogenous, hence there will be different opportunities across the asset class. Our access to industry experts, company management and other sources of information provide us with the ability to balance optimism with risks.

Market review: November 2025

EM equities slid in November 2025. Pessimism over the odds of a US interest-rate reduction in December put a cap on performance. Concerns regarding stretched valuations in artificial intelligence (AI)-related stocks also pressured global indexes. For the month, the MSCI EM Index returned -2.38%, while the MSCI World Index delivered 0.31%.

The emerging Asia region declined, with most countries reporting losses. Technology stocks in South Korea and Taiwan took heed from global sentiment and weakened from concerns over equity valuations. Also in South Korea, the market regulator’s rare caution over the share price rally of a semiconductor company hurt equities. In China, rising geopolitical tensions, this time between China and Japan, had impact on the equity market.

However, Indian equities rose. Market sentiment was largely positive, with cooling local inflation, encouraging progress toward a US-India trade deal and lower oil prices. Corporate earnings were largely positive, which also helped to buoy Indian equities upward.

Equities in the emerging Europe, Middle East and Africa region also retreated, taking cues from global markets. Weaker oil prices dampened investor sentiment for Middle Eastern equities, with disappointing corporate earnings in Saudi Arabia adding to subdued equity performance. South African equities, however, bucked the regional trend and ended higher over stronger national growth prospects and an improving fiscal outlook.

Equities in the emerging Latin America (LatAm) region advanced as a whole. An upswing in Brazilian equities supported regional performance. Lower-than-expected inflation statistics for October 2025 paved hopes that an easing cycle may be on the cards soon. Annual inflation for Mexico also decelerated in October, and the Mexican central bank reduced its benchmark interest rate further. The rate now stands at 7.25%, the lowest level since May 2022.



Copyright ©2025. Franklin Templeton. All rights reserved.

This document is intended to be of general interest only. This document should not be construed as individual investment advice or offer or solicitation to buy, sell or hold any shares of fund. The information provided for any individual security mentioned is not a sufficient basis upon which to make an investment decision. Investments involves risks. Value of investments may go up as well as down and past performance is not an indicator or a guarantee of future performance. The investment returns are calculated on NAV to NAV basis, taking into account of reinvestments and capital gain or loss. The investment returns are denominated in stated currency, which may be a foreign currency other than USD and HKD (“other foreign currency”). US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar / other foreign currency exchange rate. Please refer to the offering documents for further details, including the risk factors.

The data, comments, opinions, estimates and other information contained herein may be subject to change without notice. There is no guarantee that an investment product will meet its objective and any forecasts expressed will be realized. Performance may also be affected by currency fluctuations. Reduced liquidity may have a negative impact on the price of the assets. Currency fluctuations may affect the value of overseas investments. Where an investment product invests in emerging markets, the risks can be greater than in developed markets. Where an investment product invests in derivative instruments, this entails specific risks that may increase the risk profile of the investment product. Where an investment product invests in a specific sector or geographical area, the returns may be more volatile than a more diversified investment product. Franklin Templeton accepts no liability whatsoever for any direct or indirect consequential loss arising from use of this document or any comment, opinion or estimate herein. This document may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

Any share class with “(Hedged)” in its name will attempt to hedge the currency risk between the base currency of the Fund and the currency of the share class, although there can be no guarantee that it will be successful in doing so. In some cases, investors may be subject to additional risks.

Please contact your financial advisor if you are in doubt of any information contained herein.

For UCITS funds only: In addition, a summary of investor rights is available from here. The fund(s)/ sub-fund(s) are notified for marketing in various regions under the UCITS Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.

For AIFMD funds only: In addition, a summary of investor rights is available from here. The fund(s)/ sub-fund(s) are notified for marketing in various regions under the AIFMD Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 32a of the AIFMD Directive.

For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the fund(s)/ sub-fund(s) and will not be investing directly in the underlying assets of the fund(s)/ sub-fund(s).

This document is issued by Franklin Templeton Investments (Asia) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.

Unless stated otherwise, all information is as of the date stated above. Source: Franklin Templeton.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.